Integra LifeSciences Holdings Corp (IART) company profile
Close on Nov 17, 2026Market cap $1.05BP/E 79.7Yield –
About Integra LifeSciences
Surgical & Medical Instruments & Apparatus, SIC 3841
Integra LifeSciences Holdings Corporation manufactures and sells medical technologies across two main business segments: Codman Specialty Surgical and Tissue Technologies. The specialty surgical segment supplies neurosurgical devices, neuro-monitoring systems, cranial stabilization equipment, ultrasonic tissue ablation tools, surgical headlamps, and specialty handheld instruments. The tissue technologies segment provides regenerative biomaterials, collagen implants, porcine matrices, human placental allografts, and dressings for wound management, plastic reconstruction, and general surgery. The company also produces private-label products for other medical firms. Its customers include hospitals, outpatient surgery centers, wound clinics, integrated health networks, and medical practices.
The enterprise markets products worldwide through direct sales representatives and independent distributors, serving markets in North America, Europe, and Asia, including China, Japan, South Korea, India, and Brazil. It maintains manufacturing and research facilities in eight U.S. states and Puerto Rico, as well as in France, Germany, Ireland, Israel, and Switzerland, plus an assembly site in Suzhou, China. The excerpt does not disclose the company's headquarters location.
Summary of the business section of Integra LifeSciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Integra LifeSciences Holdings Corp
- Founded
- 1989
- Headquarters
- Princeton, NJ
- Address
- 1100 Campus Road 08540
- Phone
- (609) 275-0500
- Website
- www.integralife.com
- Employees
- 3,700, Dec 31, 2020
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, Florham Park, New Jersey
Stock & identifiers
- Ticker
- IART
- Exchange
- Nasdaq
- IPO date
- Aug 16, 1995
- Shares outstanding
- 78M, Oct 22, 2026
- Public float
- $925.10M, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jan 4, 2017; 1-for-2 reverse, May 26, 1998
- SEC CIK
- 917520
- CUSIP
- 457985208
- ISIN
- US4579852082
- FIGI
- BBG000BZJQL8
- Share class FIGI
- BBG001S7JWM6
- LEI
- WB7IJCYY8YFTENS4O147
- EIN
- 51-0317849
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Stuart Essig | President and CEO, Director | 1,785,271 |
| Mojdeh Poul | President & CEO, Director | 0 |
| Andrea B. Caruso | CVP & CHRO | 43,590 |
| Lesha R. Shinn | CVP, Chief Legal Officer & Sec | 26,838 |
| Chantal Veillon-Berteloot | EVP & CHRO | 20,772 |
| Jeffrey Mosebrook | SVP, Fin & Princ Acct Officer | 34,516 |
| Harvinder Singh | EVP & President, SS | 40,612 |
| Robert T. Davis Jr. | EVP & President, TR&DT | 66,387 |
| Lea Daniels Knight | EVP & Chief Financial Officer | 45,263 |
| Michael J. McBreen | EVP & Chief Commercial Officer | 60,743 |
| Michael Damon Hutchinson | EVP, Chief Legal Officer & Sec | – |
| Eric Schwartz | EVP, Chief Legal Officer & Sec | 56,020 |
| Christian S. Schade | Director | 90,034 |
| Barbara B. Hill | Director | 187,541 |
| Shaundra Clay | Director | 41,515 |
| Renee Wonlai Lo | Director | 35,743 |
| Jeffrey A. Graves | Director | 41,086 |
| Keith Bradley | Director | 88,254 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Jan De Witte | $282.68K | -$1.26M | $2.28M | $19 | $123 |
| FY2025 Mojdeh Poul | $9.38M | $4.26M | $2.28M | $19 | $123 |
| FY2024 De Witte | $7.49M | -$217.84K | $2.80M | $39 | $138 |
| FY2024 Jan De Witte | $7.49M | -$217.84K | $2.80M | $39 | $138 |
| FY2023 De Witte | $6.39M | $3.05M | $1.76M | $75 | $138 |
| FY2023 Jan De Witte | $6.39M | $3.05M | $1.76M | $75 | $138 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Mojdeh Poul President and Chief Executive Officer and Director | $1.01M | $350.44K | $5.22M | $2.25M | $174.56K | $371.06K | $9.38M | – |
| Lea Knight Executive Vice President and Chief Financial Officer | $638.65K | $154.90K | $1.50M | $499.57K | $77.16K | $14.00K | $2.88M | -8% |
| Robert T. Davis, Jr Executive Vice President, President, Tissue Technologies | $583.35K | $69.59K | $892.71K | $297.57K | $55.41K | $14.00K | $1.91M | -15% |
| Michael J. McBreen Executive Vice President, President, Codman Specialty Surgical | $643.75K | $212.41K | $1.33M | $442.58K | $72.78K | $14.00K | $2.71M | -14% |
| Harvinder Singh Executive Vice President, President, International | $563.99K | $91.19K | $683.13K | $227.70K | $45.43K | $14.00K | $1.63M | -38% |
| Jan De Witte Former President and Chief Executive Officer and Director | $42.31K | – | – | – | – | $240.37K | $282.68K | -96% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2020, we had approximately 3,700 full-time and part-time employees and 700 contingent, subcontracted and outsourced partners.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?